Metformin Bp Bristol Laboratories

Metformin, the active ingredient in Metformin Bp Bristol Laboratories, is a biguanide presented as a tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus. GNH USA supplies Metformin Bp Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is indicated for the management of type 2 diabetes mellitus, helping to lower elevated blood glucose levels.

- Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity.

Metformin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Metallic taste in the mouth. - Mild headache. - Decreased appetite. - Weight loss (often modest).

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe vitamin B12 deficiency leading to neuropathy. - Hepatic dysfunction. - Hypersensitivity reactions such as rash or angioedema. - Persistent gastrointestinal intolerance requiring discontinuation.

Metformin should be used with caution in specific clinical situations and patient populations. - Renal impairment: assess kidney function before initiation and periodically thereafter. - Hepatic disease: monitor liver enzymes and avoid use in severe hepatic failure. - Cardiovascular disease: use with caution in patients with unstable heart conditions. - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Pregnancy and breastfeeding: evaluate risk‑benefit ratio; generally avoided unless clearly needed. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Metformin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Certain antivirals (e.g., dolutegravir): may increase metformin levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics (especially thiazides): can affect renal function and electrolyte balance. - ACE inhibitors/ARBs: may enhance renal protective effects but require monitoring of kidney function.